Clinical efficacy of tirofiban versus ateplase in patients with minor stroke
10.3969/j.issn.1009-0126.2024.10.013
- VernacularTitle:替罗非班与阿替普酶对轻型脑卒中患者的临床疗效观察
- Author:
Shengjie HU
1
;
Shengqi FU
;
Lili ZHU
;
Haoran LI
;
Meng YU
;
Sisen ZHANG
Author Information
1. 450003 河南中医药大学第五临床医学院(郑州人民医院)神经内科
- Keywords:
stroke;
tissue plasminogen activator;
tirofiban;
prognosis
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2024;26(10):1178-1181
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of tirofiban and rt-PA alteplase in the treatment of minor stroke patients.Methods A total of 171 patients with minor stroke ad-mitted to Department of Neurology of Zhengzhou People's Hospital from January 2021 to January 2024 were prospectively and continuously enrolled,and were randomly divided into tirofiban group(84 cases)and rt-PA group(87 cases).The tirofiban group received intravenous infusion of tirofiban but not intravenous thrombolysis therapy.The rt-PA group was treated with intravenous thrombolysis.The 90-day mRS score was observed in all patients.NIHSS was used to score the improvement of neurological function.3-month all-cause death was observed during follow-up.Results The tirofiban group had a significant larger proportion of mRS score of 0-1 at 90 d(92.86％vs 82.76％,P＜0.05),lower NIHSS scores at 24 h and 7 d after treatment and smaller proportion of early neurological deterioration than the rt-PA group(P＜0.05).Larger proportion of mRS score of 0-2 in the 90 day and slightly smaller proportion of the score of 4-6 at 90 d were observed in the tirofiban group than the rt-PA group(P＞0.05).There were no statistical difference in the incidence of 3-month all-cause death between the two groups(P＞0.05).Conclusion Compared with rt-PA,tirofiban can significantly improve the clinical prognosis of pa-tients with minor stroke,reduce the risk of early neurological deterioration,and has higher safety.
